logo
First Advantage (NASDAQ:FA): Strongest Q1 Results from the Professional Staffing & HR Solutions Group

First Advantage (NASDAQ:FA): Strongest Q1 Results from the Professional Staffing & HR Solutions Group

Yahoo22-05-2025

As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at professional staffing & hr solutions stocks, starting with First Advantage (NASDAQ:FA).
The Professional Staffing & HR Solutions subsector within Business Services is set to benefit from evolving workforce trends, including the rise of remote work and the gig economy. With companies casting a wider net to find talent due to remote work, the expertise of staffing and recruiting companies is even more valuable. For those who invest wisely, the use of predictive AI in recruitment and screening as well as automation in HR workflows can enhance efficiency and scalability. On the other hand, digitization means that talent discovery is less of a manual process, opening the door for tech-first platforms. Additionally, regulatory scrutiny around data privacy in HR is evolving and may require companies in this sector to change their go-to-market strategies over time.
The 7 professional staffing & hr solutions stocks we track reported a slower Q1. As a group, revenues beat analysts' consensus estimates by 0.5% while next quarter's revenue guidance was in line.
While some professional staffing & hr solutions stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.8% since the latest earnings results.
Processing approximately 100 million background checks annually across more than 200 countries and territories, First Advantage (NASDAQ:FA) provides employment background screening, identity verification, and compliance solutions to help companies manage hiring risks.
First Advantage reported revenues of $354.6 million, up 109% year on year. This print exceeded analysts' expectations by 2.9%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates.
'We are pleased that First Advantage delivered solid financial performance in the first quarter, exceeding our expectations. We are continuing to see strong traction through upsell, cross-sell, and new logos, with sequential quarterly improvement in the base business and continued high customer retention levels. Our focused vertical strategy, with a depth of expertise across a broad range of industries, is delivering results and providing balance in the current environment,' said Scott Staples, Chief Executive Officer.
First Advantage achieved the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Unsurprisingly, the stock is up 15.5% since reporting and currently trades at $17.30.
Is now the time to buy First Advantage? Access our full analysis of the earnings results here, it's free.
Operating as a professional employer organization (PEO) that serves over 8,000 companies with more than 120,000 worksite employees, Barrett Business Services (NASDAQ:BBSI) provides management solutions that help small and mid-sized businesses handle human resources, payroll, workers' compensation, and other administrative functions.
Barrett reported revenues of $292.6 million, up 10.1% year on year, outperforming analysts' expectations by 2.3%. The business had an exceptional quarter with an impressive beat of analysts' EPS estimates.
The market seems content with the results as the stock is up 2% since reporting. It currently trades at $41.60.
Is now the time to buy Barrett? Access our full analysis of the earnings results here, it's free.
With roots dating back to 1948 as the first specialized recruiting firm for accounting and finance professionals, Robert Half (NYSE:RHI) provides specialized talent solutions and business consulting services, connecting skilled professionals with companies across various fields.
Robert Half reported revenues of $1.35 billion, down 8.4% year on year, falling short of analysts' expectations by 4.3%. It was a disappointing quarter as it posted a significant miss of analysts' EPS estimates.
Robert Half delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 1.9% since the results and currently trades at $45.58.
Read our full analysis of Robert Half's results here.
Founded during the post-World War II economic boom when businesses needed temporary workers, ManpowerGroup (NYSE:MAN) connects millions of people to employment opportunities through its global network of staffing, recruitment, and workforce management services.
ManpowerGroup reported revenues of $4.09 billion, down 7.1% year on year. This number topped analysts' expectations by 2.9%. However, it was a slower quarter as it logged a significant miss of analysts' EPS guidance for next quarter estimates and a significant miss of analysts' EPS estimates.
The stock is down 13.6% since reporting and currently trades at $42.72.
Read our full, actionable report on ManpowerGroup here, it's free.
Born from a corporate spinoff in 2017 to focus on employee experience technology, Alight (NYSE:ALIT) provides human capital management solutions that help companies administer employee benefits, payroll, and workforce management systems.
Alight reported revenues of $548 million, down 2% year on year. This result surpassed analysts' expectations by 1.2%. It was a strong quarter as it also recorded an impressive beat of analysts' EPS guidance for next quarter estimates and full-year revenue guidance meeting analysts' expectations.
Alight had the weakest full-year guidance update among its peers. The stock is up 4.5% since reporting and currently trades at $5.47.
Read our full, actionable report on Alight here, it's free.
Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Yahoo

time29 minutes ago

  • Yahoo

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Palantir Technologies Hit a New All-Time High on Wednesday
Why Palantir Technologies Hit a New All-Time High on Wednesday

Yahoo

time42 minutes ago

  • Yahoo

Why Palantir Technologies Hit a New All-Time High on Wednesday

One Wall Street analyst boosted Palantir's price target, despite maintaining a sell rating. The reasoning for the move was decidedly bullish. The key factor in the rating is Palantir's frothy valuation. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock continued its epic run on Wednesday, climbing as much as 5.4%. As of 3:37 p.m. ET, the stock was still up 3%. The artificial intelligence (AI) software and data mining specialist has climbed to new heights several times in recent weeks, with its stock notching a new all-time high on Wednesday. That puts the stock up more than 80% so far this year. The catalyst behind today's move was a reluctant nod from a Wall Street analyst. Mizuho analyst Matthew Broome kept an underperform (sell) rating on Palantir stock, but raised his price target for Palantir to $116, up from its previous level of $94. For those keeping score at home, that's roughly 12% below the stock's closing price on Tuesday, so the analyst is obviously playing catch-up. Broome cited Palantir's "strong recent execution and significant upward revisions" for his price target increase. The analyst also noted the company's "strong strategic positioning with large customers and potential for further accelerated growth in future years." So, if the analyst is so bullish on Palantir, why maintain the sell rating? In a word: valuation. Palantir stock is currently selling for 594 times earnings and 109 times sales. With multiples of that magnitude, it isn't for the faint of heart. Even factoring in the company's accelerating growth, it sports a price-to-earnings growth (PEG) ratio of 6, when any number higher than 1 is overvalued. Don't get me wrong: I'm a dyed-in-the-wool Palantir bull. However, valuation is a fickle mistress, and any failure by the company to execute -- real or perceived -- could bring the stock crashing down. In fact, I wouldn't be surprised to see Palantir stock get cut in half at some point over the next year -- before climbing to even greater heights. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Danny Vena has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Why Palantir Technologies Hit a New All-Time High on Wednesday was originally published by The Motley Fool

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives
RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives

Yahoo

timean hour ago

  • Yahoo

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives

LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) ('RadNet'), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the 'Second Amendment') to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the 'Existing Credit Agreement' and, as amended by the Second Amendment, the 'Credit Agreement'). Pursuant to the Second Amendment, Barclays Bank PLC, as lender, committed to provide RadNet an incremental term loan in the aggregate principal amount of $100.0 million (the '2025 Incremental Term Loan'), which will be added to and form a part of the existing term loan under the Existing Credit Agreement (the 'Existing Term Loan,' together with the 2025 Incremental Term Loan, the 'Term Loan'). The 2025 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $868.4 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $2.4 million compared to approximately $2.2 million prior to the entry of the Second Amendment. All other terms and covenants of the Credit Agreement (as amended by the Second Amendment) remain unchanged. The proceeds of the 2025 Incremental Term Loan will be used to finance future acquisitions and for other general corporate purposes, providing RadNet with additional flexibility to pursue strategic growth opportunities across its national imaging center network and technology platforms. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, 'We appreciate the continued support of Barclays and our relationship banks and term-loan lenders. This incremental financing increases our capacity to execute on a pipeline of acquisition opportunities while maintaining our conservative capital structure. The proceeds of approximately $100 million adds to the $717 million cash balance as of March 31, 2025, positioning us to advance our growth strategy and create long-term value for our stockholders.'RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store